Article
Author(s):
The American Association of Dispensing Ophthalmologists Inc. (AADO) will provide educational programs during the continuing education component of International Vision Expo East, March 22 to 25 at the Jacob K. Javits Center in New York City.
The American Association of Dispensing Ophthalmologists Inc. (AADO) will provide educational programs during the continuing education component of International Vision Expo East, March 22 to 25 at the Jacob K. Javits Center in New York City.
AADO officers-President Vincent K. Young, MD; Executive Director Pamela B. Fritz; and Secretary Katherine McNelis, COA, NCLC, FNAO-will present classes and moderate a series of AADO-endorsed dispensing ophthalmology roundtables.
Classes:
Accreditation: National Contact Lens Examiners (NCLE), American Optometric Association (AOA) Paraoptometric; accredited for the New York state-licensed opticians
Instructors: Vincent K. Young, MD
Accreditation: American Board of Opticians (ABO), Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO), AOA Paraoptometric; accredited for the New York state-licensed opticians
Instructors: Pamela B. Fritz
Accreditation: ABO
Instructors: Vincent K. Young, MD
Accreditation: ABO, JCAHPO, AOA Paraoptometric, NCLE; accredited for the New York state-licensed opticians
The dispensing ophthalmology roundtables will be Saturday, March 24, from 4:30 to 5:30 p.m. in the Crystal Palace of the Javits Center, E Hall, Concourse Level.
VEE attendees may participate in any one roundtable discussion. For a practice to maximize the experience, however, staff members-for example, a physician and a key dispensary staff member-should participate in separate roundtables. Every participant will receive the "Roundtable Companion Notebook," which summarizes all roundtable topics.
Roundtables:
Admission to the roundtables is free, but because space is limited, pre-registration is required. Register online at http://www.aado.net/ or call toll-free 800/705-AADO (2236).
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial